Insulet Corporation (PODD) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposa...
Insulet Corporation (PODD) currently trades at a P/E ratio of 33.42 (historical range: 30.90–105.56, median: 48.47), placing it at the 3th percentile — cheap relative to its history, P/S ratio of 3.49 (range: 3.23–11.04, 3th percentile — cheap relative to its history).
Over the historical period (2024-08-30 to 2026-08-28), Insulet Corporation's P/E ratio has expanded by 18% over the observed period (from an average of 55.2 to 65.4).
Insulet Corporation appears significantly undervalued relative to its historical range, trading at depressed multiples across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 33.42 | 30.90 | 48.47 | 105.56 | 3th | cheap relative to its history |
| P/S Ratio | 3.49 | 3.23 | 8.77 | 11.04 | 3th | cheap relative to its history |
| FCF Yield | 0.01 | 0.00 | 0.01 | 0.03 | 34th | above its historical average |